Novocure LTD Form 4 insider transactions

NovoCure's Chief Operating Officer, Mukund Paravasthu, sold 160 ordinary shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

NovoCure's General Counsel, Ben Arye Barak, acquired 930 ordinary shares through the company's Employee Share Purchase Plan (ESPP) at a discounted price of $12.24 per share on June 28, 2024.

Wilhelmus CM Groenhuysen, Chief Operating Officer of NovoCure Ltd, acquired 1,055 ordinary shares through the company's Employee Share Purchase Plan (ESPP) at a price of $12.24 per share.

NovoCure's CEO, Asaf Danziger, acquired 1,239 ordinary shares through the company's Employee Share Purchase Plan (ESPP) at a price of $12.24 per share on June 28, 2024.

Ashley Cordova, CFO of NovoCure Ltd, reports acquiring 1,286 ordinary shares through the company's Employee Share Purchase Plan (ESPP) at a price of $12.24 per share.

Frank X. Leonard, EVP and President of Novocure Oncology, acquired 1,736 ordinary shares of NovoCure Ltd through the company's Employee Share Purchase Plan (ESPP) at a price of $12.24 per share.

Michal Nath Puri, Chief Human Resources Officer at NovoCure, reports acquiring 1,736 ordinary shares through the company's Employee Share Purchase Plan (ESPP).

Ashley Cordova, CFO of NovoCure Ltd, sold 688 ordinary shares on August 2, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

Wilhelmus CM Groenhuysen, COO of NovoCure, exercised stock options and acquired 124,373 ordinary shares on June 5, 2024.

Director Allyson J. Ocean reports acquisition of restricted stock units and stock options in NovoCure Ltd.

Director Martin J. Madden acquired shares and options in NovoCure Ltd, as reported in a recent SEC filing.

Director David Hung acquired 4,053 restricted stock units and options to buy 6,229 ordinary shares of NovoCure Ltd on June 5, 2024.

Director Kristin Stafford acquired shares and options in NovoCure Ltd on June 5, 2024, through restricted stock units and stock options.

Director Anthony Vernon W. of NovoCure Ltd. reports the sale of 964 ordinary shares at an average price of $23.893 and the acquisition of 4,053 restricted stock units and options to buy 6,229 ordinary shares.

Director Timothy J. Scannell reports the sale of 964 ordinary shares and acquisition of 4,053 restricted stock units and 6,229 stock options in NovoCure Ltd.

Director Gabriel Leung of NovoCure Ltd. reports the sale of 964 ordinary shares and the acquisition of 4,053 restricted stock units.

Director Jeryl L. Hilleman reports the acquisition of restricted stock units and stock options in NovoCure Ltd.

Wilhelmus CM Groenhuysen, Chief Operating Officer of NovoCure Ltd, sold shares to cover tax withholding obligations related to vesting Restricted Stock Units.

Frank X. Leonard, EVP and President of Novocure Oncology, sold shares of NovoCure Ltd to cover tax withholding obligations related to vesting Restricted Stock Units.

Ashley Cordova, CFO of NovoCure Ltd, reports the acquisition of shares and stock options in the company.

Frank Leonard, EVP and President of Novocure Oncology, reports the acquisition and disposal of NovoCure Ltd shares, including the vesting of restricted stock units and a sale to cover tax obligations.

Michal Nath Puri, Chief Human Resources Officer at NovoCure, reports acquisition and disposal of ordinary shares and stock options.

Uri Weinberg, Chief Innovation Officer of NovoCure Ltd, reports the acquisition of ordinary shares and stock options.

NovoCure's Chief Medical Officer, Nicolas Leupin, reports the acquisition of ordinary shares and stock options.

Moshe Giladi, Chief Science Officer of NovoCure Ltd, reports the acquisition of shares and stock options, as well as the disposal of shares, in a recent SEC Form 4 filing.

Barak Ben Arye, General Counsel of NovoCure, reports acquisition of shares through an employee share purchase plan and restricted share units, along with stock option grants.

Wilhelmus Groenhuysen, Chief Operating Officer of NovoCure, reports transactions involving the company's ordinary shares, including acquisitions through an employee share purchase plan and sales to cover tax obligations.